| 
                      
 
 ~ Antenatal Corticosteroid ~ 1. Benefits of prenatal corticosteroid therapy: Ÿ The greatest benefit is achieved if more   
than 24 hrs and less than 7 days. Ÿ Infants born within 24 hrs or more than   
7 days also show:   
    
    i mortality i incidence or severity of respiratory   
    distress syndrome i intraventricular hemorrhage i requirement for oxygen and ventilatory   
    support i neonatal costs and length of stay in   
    NICU 2. Indications: Ÿ The most significant benefit is seen   
between 24 and 34 weeks of gestation Ÿ All pregnant women between 24 and 34   
weeks of gestation should be considered candidates for   
    
    corticosteroid therapy 3. Contraindications: Ÿ Any clinical suspicion or evidence of   
intrauterine infection Ÿ Caution should be exercised in   
coexisting conditions maybe adversely affected:   
    
    - severe hypertensive disorders in pregnancy - intrauterine growth restriction - diabetes mellitus - Rh isoimmunization - peptic ulcer disease 4. Recommended regimens for fetal maturation: Ÿ Betamethasone: 12mg given im. every 24   
hrs ´ 2 doses Ÿ Dexamethasone: 6mg given im. every 12   
hrs ´ 4 doses Ÿ Prenatal Corticosteroids should be   
administered even if delivery is expected to occur before the second dose.   
 Antenatal corticosteroids   
outweight the potential risk: reduction in the risk of RDS but also a   
  substantial reduction in mortality and IVH  
all fetus between 24 and 34 weeks gestation at risk  
eligible for therapy with tocolytics should also be eligible for treatment   
  with antenatal corticosteriods  
treatment consists of two dose of 12 mg of betamethasone given   
  intramuscularly 24 hours apart or four doses of 6 mg dexamethasone given   
  intramuscularly 12 hours apart. Optimal benefit begins 24 hours after   
  initiation of therapy and lasts 7 days.  
Treatment for less 24 hours is still associated with significant reduction   
  in neonatalmortaility, RDS, and IVH.  
PPROM < 30-32 weeks’ gestation in the absence of clinical   
  choriomamnionitis, corticosteriod is recommended because of the high risk of   
  IVH at these early gestational ages.  
In complicated pregnancies where delivery prior to 34 weeks’ gestation is   
  likely, antenatal corticosteriod use is recommended unless there is evidence   
  that corticosteriods will have an adverse effect on the mother or delivery is   
  imminent.   
  
   |